Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

COUCH Medcomms

- PMLiVE

Fox&Cat appoints Kim Walker as partner and managing director

Walker most recently served as managing director of GCI Health London

- PMLiVE

Innovation’s one real law

Playing with the NIH risks unintended consequences

- PMLiVE

The Cat’s Out of the Bag… Kim Walker, ex-GCI Health, Joins Fox&Cat as Partner and Managing Director

Fox&Cat appoints Kim Walker as Partner and Managing Director, bringing leadership strength and operational focus to the agency. Her arrival enhances Fox&Cat’s ADAPT™ methodology and consultancy model, reinforcing its commitment...

Fox&Cat

- PMLiVE

Merck gains rights to Hengrui’s heart disease candidate in deal worth almost $2bn

Cardiovascular diseases result in an estimated 17.9 million global deaths each year

- PMLiVE

Sanofi’s investigational MS treatment tolebrutinib granted FDA priority review

Approximately 2.9 million people worldwide are living with the neurodegenerative disease

- PMLiVE

UKHSA releases list of pathogens posing ‘greatest risk’ to public health

The agency has listed 24 pathogen families where preparedness efforts are most needed

- PMLiVE

Mastering KAM excellence: achieving meaningful growth from top accounts

By Aaron Bean

- PMLiVE

Novo Nordisk gains rights to United Laboratories’ triple receptor agonist in deal worth $2bn

UBT251 is in early-stage clinical development for type 2 diabetes, obesity and other diseases

- PMLiVE

Novartis’ Fabhalta granted FDA approval to treat ultra-rare kidney disease C3G

Approximately half of C3G patients progress to kidney failure within ten years of diagnosis

- PMLiVE

GSK to explore link between Shingrix and dementia risk in new UK research collaboration

More than 55 million people worldwide are currently living with the neurodegenerative disease

- PMLiVE

Breaking boundaries in medical affairs: how measurable outcomes redefine success

By Caroline Phillips

- PMLiVE

Live Q&A: Beyond NHS England – Restructuring and its implications for Pharma and Medtech

What does the abolition of NHS England mean for your market access and NHS Engagement strategy? How will the changes at national and integrated care board (ICB) level impact launch...

Petauri Evidence

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links